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Abstract
Neurodegenration is a pathological hallmark of Alzheimer’s disease (AD), but the underlying molecular mechanism remains
elusive. Here, we present evidence that reveals a crucial role of Wnt5a signaling in this process. We showed that Wnt5a and
its receptor Frizzled-5 (Fz5) were up-regulated in the AD mouse brain, and that beta-amyloid peptide (Ab), a major
constituent of amyloid plaques, stimulated Wnt5a and Fz5 expression in primary cortical cultures; these observations
indicate that Wnt5a signaling could be aberrantly activated during AD pathogenesis. In support of such a possibility, we
observed that inhibition of Wnt5a signaling attenuated while activation of Wnt5a signaling enhanced Ab-evoked
neurotoxicity, suggesting a role of Wnt5a signaling in AD-related neurodegeneration. Furthermore, we also demonstrated
that Ab-induced neurotoxicity depends on inflammatory processes, and that activation of Wnt5a signaling elicited the
expression of proinflammatory cytokines IL-1b and TNF-a whereas inhibition of Wnt5a signaling attenuated the Ab-induced
expression of the cytokines in cortical cultures. Our findings collectively suggest that aberrantly up-regulated Wnt5a
signaling is a crucial pathological step that contributes to AD-related neurodegeneration by regulating neuroinflammation.
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Introduction
Beta-Amyloid (Ab) peptide is a dominant candidate of the
causative agents for Alzheimer’s disease (AD) [1,2]. According to
the widely-held amyloid hypothesis of AD, Ab initiates an array of
molecular and cellular cascades that eventually lead to progressive
neuronal dysfunction and degeneration [1,2]. However, mecha-
nistic molecular processes that link Ab and neurodegeneration
remain to be firmly established.
Chronic neuroinflammation associated with persistent glial
activation is a major disease process evoked by Ab and intimately
associated with the progress of AD pathologies [3,4]. Previous
studies suggest that neuroinflammation contributes to the
development of neurodegenerative hallmarks in AD brains,
including Ab plaques [4] and tau tangles [5,6,7]. AD therapeutic
approaches that target neuroinflammation are under develop-
ment [8,9,10,11]. AD neuroinflammation is likely triggered
by Ab-mediated activation of microglia and astrocytes [3,4,
12,13,14]. It was reported that Ab induces the expression of
cytokines (including IL-1b,T N F - a, IL-6, and IL-8) in cultured
astrocytes and microglia [15,16,17,18]. Mounting evidence
suggests that Ab may activate glial cells via specific sensor
receptors such as toll-like receptors (TLR), receptors for advanced
glycoxidation end-products (RAGE) and NOD-like receptors
(NLR) [4]. Despite the significant understandings on the
induction of AD neuroinflammation, the downstream molecular
processes that are elicited by Ab and regulate the inflammation
remain poorly understood.
Wnts are secreted signaling proteins that play important roles in
neural development and plasticity [19,20,21,22]. Multiple lines of
evidence indicate a critical role of Wnt signaling in AD [22]. b-
catenin, a key downstream effector protein in the canonical Wnt
signaling pathway, interacts with and is regulated by presenilin
[23,24,25]. Glycogen synthase kinase (GSK)-3, a central serine/
threnine kinase in the canonical Wnt signaling pathway, plays a
critical role in the regulation of Ab production [26] and
aggregation [27] and in tau phosphorylation [28]. Genetic studies
revealed that LRP6 polymorphisms are causally linked to AD [29].
In AD brains, canonical Wnt signaling is impaired [30], and
DKK1, an antagonist of Wnt signaling, is upregulated [31,32].
Importantly, Ab was reported to inhibit Wnt signaling by directly
binding to the Frizzled receptors [33]. The impairment of
canonical Wnt signaling is likely etiologically significant, because
forced up-regulation of the canonical Wnt signaling pathway has
rescuing effects on the development of AD-related phenotypes in
both neuron cultures and animal models [27,30,34,35]. In contrast
to the canonical pathway, the involvement of non-canonical Wnt
signaling pathways in the regulation of AD pathogenesis is less
clear. A recent study indicates that Wnt5a-activated non-canonical
Wnt signaling antagonizes Ab synaptotoxicity [36].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22920In this paper, we report an important role of Wnt5a signaling in
the regulation of Ab-evoked neurotoxicity and neuroinflamma-
tion. We observed that (1) Wnt5a/CaMKII signaling is up-
regulated at the early stages of AD development in an APPswe/
PSEN1DE9 transgenic mouse model, (2) Ab activates Wnt5a
signaling in primary cortical cultures, (3) Ab-induced Wnt5a up-
regulation is a critical molecular step leading to the development
of Ab neurotoxicity in cultures, (4) Wnt5a stimulates inflammatory
processes, and (5) Wnt5a is critical for Ab-induced inflammatory
response. Our results suggest that abnormally up-regulated non-
canonical Wnt5a signaling may regulate chronic neuroinflamma-
tion in AD brains.
Materials and Methods
Preparation of Ab42 peptides
Recombinant human Ab (1–42) (Chemicon) was used to
prepare monomers (Ab-mon), oligomers (Ab-olig) and fibrils
(Ab-fib), as described [37]. For monomer preparation, 5 mM
Ab42 in DMSO was diluted directly with cell culture media. For
oligomer preparation, 5 mM Ab42 in DMSO was diluted to
100 mM in ice-cold D-MEM/F-12 (Invitrogen), vortexed for 300,
centrifugated (10,000 g; room temperature) for 19, and incubated
at 4uC for 24 h. For fibril preparation, 10 mM HCl was added to
the Ab42 solution (5 mM in DMSO) to bring Ab to a final
concentration of 100 mM, vortexed for 300, centrifugated
(10,000 g, room temperature) for 19, and incubated with shaking
at 37uC for 24 h. Products from such preparations are mixtures
that contain Ab monomers and the intended aggregates [37]. The
quality of the preparations was confirmed by Western blotting
analysis with the 6E10 (Covance; 1:5000), and the molecular mass
was estimated by rainbow pre-stained protein markers (GE
Healthcare).
Animals and hippocampus dissection
All procedures were approved by Animal Care and Use
Committees of the University of Texas Medical Branch. Male
APP (amyloid precursor protein)/presenilin-1 double transgenic
(APPswe/PSEN1DE9, 26Tg) mice [38] and wild-type littermates
at 3.5 months of age were anesthetized and then decapitated. The
hippocampi were rapidly collected on ice for Western blotting,
immunohistochemistry, or fluorescent immunostaining..
Neuron cultures
C57BL E18 cortical cultures were prepared, as described [39].
The cells were plated on poly-D-lysine (30,000–70,000; Sigma) -
coated dishes at a density of 1.5610
5 cells/cm
2. Immunostaining
with cell-type markers indicate that the cultures are mixtures of
neuron (,60%) and glial cells (,40%). Cultures at 12–14 DIV
were used in this study. All experimental treatments were carried
out by adding the administrated agents into the freshly changed
culture media. Only morphologically healthy neuronal cultures
were used for drug treatments.
Western blotting and antibodies
Western blotting was performed as described [40]. The intensity
of non-saturated bands on Western blots was quantified by
densitometry analysis with NIH ImageJ. GAPDH or b-actin were
used as loading controls. Rabbit-anti-APP antibody was from
Sigma-Aldrich (1:3000); rabbit-anti-Wnt5a (1:1000) and rabbit-
anti-Fz5 (1:1000) antibodies were from Abcam; rabbit-anti-p-
aCaMKII(Thr286) (1:1000), rabbit-anti-NIK (1:1000), and rabbit-
anti-IkB-a (1:1000) antibodies were from Cell Signaling Technol-
ogy; and mouse-anti-GAPDH (1:1000) and rabbit-anti-b-actin
(1:1000) antibodies were from Santa Cruz Biotechnology.
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed on 5 mm-thick paraffin-
embedded sections. The sections were deparaffined, dehydrated
and treated with 1% H2O2 as decribed [41] Antigen retrieval was
carried out using citrate buffer (0.01 M; pH 6.0). The sections
were then incubated with the primary antibody recognizing Ab
(1–40/42) (Millipore; 1:100) overnight at 4uC followed by
incubation with biotinylated goat anti-rabbit IgG. After treatment
with streptavidin-HRP and staining with DAB, the sections were
stained with hematoxylin and mounted. Indirect fluorescence
immunostaining was performed, as described [42].with rabbit
anti-Wnt5a (abcam; 5 mg/ml) and rabbit anti-Fz5 (abcam; 1 mg/
ml) primary antibodies and Cy3-conjugated donkey anti-rabbit
secondary antibody (Jackson ImmunoResearch; 1:200).
Measurement of secreted cytokines
Cortical cultures (12–14 DIV) were treated with Wnt5a
(200 ng/ml), and media were collected at 0.5, 1, 2, 6, 12 and
24 h after Wnt5a application. Tumor necrosis factor alpha (TNF-
a) and interleukin 1 beta (IL-1b) in collected media were
quantified using Mouse TNF-a or IL-1b Quantikine ELISA Kits
(R&D Systems), respectively.
MTT assay and trypan blue staining
The MTT assay and trypan blue staining were performed as
described in [43]. Three independent experiments were performed
Figure 1. Ab increases significantly in the hippocampus of the APPswe/PSEN1DE9 (26Tg) mouse at the age of 3.5 months. A, APP in
the wild-type and 26Tg hippocampus (3.5-months). B. APP processing in the hippocampus revealed by immunoblotting with the monoclonal
antibody 6E10 (recognizing residues 1–16 of Ab). C. Immunohistochemical staining of the hippocampus with 6E10. Note the clustered Ab signals
(arrows) in the cell body layer of the 26Tg hippocampus. Similar results were obtained from 6 pairs of wild-type and 26Tg mice.
doi:10.1371/journal.pone.0022920.g001
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Reagents: 3% hydrogen peroxide solution (Sigma-Aldrich);
recombinant mouse Wnt-5a (R&D Systems); anti-mouse Wnt-5a
antibody (R&D Systems); anti-Fz5 antibody (against the extracel-
lular cysteine-rich domain of human Fz5) (R&D Systems); Foxy5
peptide (Inbiolabs); Box5 peptide (Inbiolabs); recombinant mouse
IL-10 (R&D Systems); and activated protein C (APC) (Sigma-
Aldrich).
Statistical analysis
Data were expressed as the means 6 SEM. Statistical analysis
was performed with the Prism software (GraphPad). We used the
Student’s two-tailed t-test for statistical comparisons between any
two groups, and one-way ANOVA analyses with a Bonferroni
post-hoc test for comparisons between multiple groups.
Results
Increased expression of key proteins in the non-canonical
Wnt signaling pathway in the hippocampus of AD mouse
models
Previous studies revealed down-regulation of canonical Wnt
signaling in the brain of APPswe/PSEN1DE9 AD mouse models
[27]. Consistent with these findings, we observed decreased
expression of proteins in the canonical pathway, including Wnt3a,
Fz1 and b-catenin (data not shown). In contrast, in preliminary
studies, we also observed up-regulated expression of several
proteins implicated in the non-canonical Wnt signaling pathway,
including Wnt5a and its receptor Fz5, at various postnatal stage
(3.5–9.5 months). At 3.5 months of age, APP transgene was clearly
expressed (Fig. 1A). APP processing expected to generate Ab was
evident in the transgenic hippocampi (Fig. 1B). In addition,
immunohistochemistry staining with an antibody that recognized
Ab revealed clustered signals in the cell body layer (Fig. 1C), which
may include Ab that starts accumulating. Because memory deficits
have not manifested at this stage [44], we reasoned that the up-
regulation of non-canonical Wnt signaling is potentially an early
molecular abnormality during AD pathogenesis. Therefore, we
performed more detailed analysis on the non-canonical Wnt
signaling in mice at 3.5 months of age. Western blotting analysis
showed that, compared with wild-type controls, Wnt5a protein
increased 1.5 fold in the hippocampus of the 26Tg mouse
(p,0.01; Fig. 2A). Similarly, Fz5 protein was also significantly up-
regulated in the 26Tg hippocampus (1.6 fold; p,0.01; Fig. 2B).
Because activation of non-canonical Wnt signaling can cause
aCaMKII phosphorylation [45], we next determined the protein
level of phosphorylated aCaMKII (pT286-aCaMKII). pT286-
aCaMKII was increased 2.6 fold (p,0.05; Fig. 2C). Fluorescent
immunostaining showed that, in comparison with control, the
increase of Wnt5a (Fig. 2D) and Fz5 (Fig. 2E) occurred in all
hippocampal fields, including CA1, CA2/CA3 and dentate gyrus
(DG), of the 26Tg mouse, which resembled the spatial pattern of
Ab plaques (Fig. 1C). These data together suggest that non-
canonical Wnt signaling is up-regulated in the 26Tg AD
hippocampus.
Rapid up-regulation of non-canonical Wnt signaling by
Ab oligomers in primary neuron culture
We next sought to understand the mechanism by which non-
canonical Wnt signaling is activated in the AD mouse brain.
Because Ab is a key pathological agent for AD, we hypothesized
that it causes the up-regulated expression of Wnt5a and other
relevant proteins measured in 26Tg mice. To test this hypothesis,
Figure 2. Wnt5a/CaMKII signaling is up-regulated in the
hippocampus of the 26Tg AD mouse model. A, B, and C. Protein
levels of Wnt5a (A), Fz5 (B) and pT286-aCaMKII (C) in the wild-type and
26Tg hippocampus. In summary graphs of quantitative data, the levels of
target proteins were normalized with the b-actin loading control and
expressed as relative units to the wild-type controls. Data presented in
graphs are means 6 SEM from six pairs of mice. * p,0.05. D and E.
Distribution of Wnt5a (D) and Fz5 (E) protein in the wild-type and 26Tg
hippocampus. DAPI staining was performed to visualize the cell bodies.
doi:10.1371/journal.pone.0022920.g002
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in mouse cortical cultures (12–14 DIV). A wide range of Ab
concentrations (100 nM - 15 mM) have been used in previous in
vitro studies. We chose to use a relatively low Ab concentration
(500 nM) to better reflect the fact that the proteins are up-
regulated at early AD stages when Ab begins to accumulate
(Fig. 1C). Prior works have shown that 500 nM Ab is efficient to
initiate some of the earliest and reversible AD-relevant pathologies
[46,47]. More recent studies have indicated that different forms of
Ab (monomer, oligomer and fibril) vary in their AD-related
toxicity, with the oligomer being considered the most toxic form
[37,48]. We prepared the oligomers and fibrils of Ab (1–42)
(Fig. 3A) and compared the effect of Ab monomers, oligomers and
fibrils on Wnt5a, Fz5 and pT286-aCaMKII protein expression in
cortical cultures. As shown in Fig. 3B–D, Ab oligomer treatment
for 24 h caused significant increases in Wnt5a (1.4 fold; p,0.05),
Fz5 (1.4 fold; p,0.01) and pT286-aCaMKII (1.7 fold; p,0.01).
Under the same experimental conditions, preparations of
monomers and fibrils caused changes with lower magnitudes
(Fig. 3B–D). Next, we investigated the dose effects of the oligomer.
As shown in Fig. 3E–G, the oligomer increased expression of
Wnt5a, Fz5, and pT286-aCaMKII proteins in a concentration-
dependent manner (50 nM–5 mM). Although Wnt5a and p-
CaMKII displayed a clear dose-effect at 24 hours after treatment,
Fz5 showed this effect at 30 min. In addition, 500 nM of Ab
oligomer caused a time-dependent increase in Wnt5a (Fig. 3H).
Figure 3. Up-regulation of proteins in the non-canonical Wnt signaling pathway by Ab peptide in cortical neuron cultures. A.
Western blot analysis of the preparations of Ab (1–42) oligomers and fibrils. Ab preparations were, separated on SDS–PAGE (4–12% NuPAGE bis-Tris
gel), and probed with the monoclonal antibody 6E10.. B, C, and D. Protein levels of Wnt5a (B), Fz5 (C) and pT286-aCaMKII (D) in cortical cultures
treated with 500 nM of monomeric, oligomeric, and fibrillar Ab peptide for 24 hrs. E, F, and G. Concentration-dependent effects of Ab oligomer on
the protein levels of Wnt5a (E), Fz5 (F) and pT286-aCaMKII (G). Although the dose effect of Ab on Wnt5a was most clearly observed at 24 hours post
Ab administration, the effect on Fz5 could be observed at 30 min. H. Time course of the Ab oligomer effects (500 nM) on Wnt5a. In summary graphs
of quantitative data, the levels of target proteins were normalized against GAPDH or b-actin and expressed as relative units to the vehicle-treated
controls. Data in summary graphs are means 6 SEM from three independent experiments. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0022920.g003
Wnt5a in AD
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22920Figure 4. Wnt5a signaling regulates Ab neurotoxicity. The MTT assay was used to measure cell viability in cortical cultures at 24 hrs after
indicated treatments. A. Cell survival rates in cultures challenged with Ab oligomers, H2O2, or a combination of Ab oligomers and H2O2. B. Cultures
challenged with Ab (500 nM) and H2O2 (100 mM) in the presence of Wnt5a at different concentrations. C. Cultures challenged with Ab and H2O2 in
the presence of anti-Wnt5a or ant-Fz5 antibodies. D. Effects of Foxy5 on the neurotoxicity of Ab/H2O2. E. Effects of Box5 on the neurotoxicity of Ab/
H2O2. Data are expressed as mean 6 SEM (n$12 from three independent experiments). * p,0.05; ** p,0.01; *** p,0.001. # p,0.05 (vs. the group of
Wnt5a in AD
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signaling is up-regulated by Ab peptide, especially the oligomers.
Suppression of Wnt5a signaling alleviates Ab
neurotoxicity
The observations of the upregulation of the Wnt5a signaling in
early AD mouse brains and by Ab in cortical cultures suggest a
potential role of Wnt5a signaling in AD pathogenesis. We next
sought to directly test this idea by determining the significance of
Ab-mediated Wnt5a up-regulation on Ab cytotoxicity in cortical
cultures. Previous work revealed concentration-dependent neuro-
toxicity of Ab peptides [37,49,50], with high concentrations of Ab
(.5.0 mM) causing neuron death in cultures and low concentra-
tions of Ab (0.1,1.0 mM) sensitizing neurons to become
vulnerable to further stresses [50]. To mimic the early AD brain
condition when the non-canonical Wnt signaling proteins are
aberrantly upregulated, in these experiments we used a relatively
low concentration (500 nM) of Ab that can upregulate Wnt5a and
Fz5 (Fig. 3). Ab oligomer at this concentration did not cause cell
death, as measured by MTT assays (Fig. 4A). We also used trypan
blue staining to confirm this observation (Fig. S1). This finding is
consistent with the idea that in the early stages of AD pathogenesis
Ab may not cause neuron death. Next, we wanted to investigate if
Ab at this concentration causes the cells to become more
vulnerable to detrimental stresses that are relevant to AD
pathogenesis. To this end, we tested the effect of Ab on the
sensitivity of the cultures to hydrogen peroxide (H2O2) stresses.
Hydrogen peroxide was chosen because it is generated during the
very early stages of aggregation of the amyloid peptides [51] and is
critically involved in AD pathogenesis [49,52]. At low concentra-
tions (25–100 mM), hydrogen peroxide did not cause cell death by
itself; however, when co-administrated with Ab oligomers
(500 nM) it caused marked cell death (Fig. 4A, Fig. S1). These
results indicate that neurons exposed to 500 nM Ab are more
vulnerable to other detrimental factors. We also showed that H2O2
neither stimulated aCaMKII phosphorylation by itself nor
significantly enhanced the Ab-induced phsphorylation (Fig. 4F),
indicating that H2O2 did not activate the non-canonical pathway.
To determine the potential role of Wnt5a up-regulation in Ab-
induced sensitization to H2O2 stress, we neutralized Wnt5a in
media with specific anti-Wnt5a antibody. As shown in Fig. 4C, the
antibody (0.5–8.0 mg/ml) displayed a rescue effect on cell death in
a concentration-dependent manner, which reached statistical
significance after 4.0 mg/ml. Recent studies identified a modified
Wnt5a-derived hexapeptide (Box5) that can specifically antagonize
Wnt5a in malignant melanoma cells [53]. Similar to the anti-
Wnt5a antibody, Box5 also had a rescue effect on Ab/H2O2-
induced cell death in a concentration-dependent manner (Fig. 4E).
Because Fz-5 is a Wnt5a receptor [54], we further tested the effect
of anti-Fz5 antibody (against the extracellular cystein-rich
domain). Consistent with the findings with anti-Wnt5a antibody
and Box5, the anti-Fz5 antibody also had a rescue effect (Fig. 4C).
We further tested the effect of, anti-Wnt5a, anti-Fz5 antibodies
and Box5 on the phosphorylation of aCaMKII, a molecular
marker of the activation of the non-canonical Wnt/Ca
2+ pathway.
The results showed that all these reagents significantly blocked
Ab/H2O2-induced up-regulation of p-aCaMKII (Fig. 4G), and
thus provide an independent molecular confirmation of the
activity of anti-Wnt5a, anti-Fz5 antibodies and Box5. These
results together strongly suggest that Ab-induced Wnt5a up-
regulation at least partially mediates Ab neurotoxicity.
Exogenous Wnt5a potentiates Ab neurotoxicity
Because Ab-induced Wnt5a up-regulation is critical for Ab
neurotoxicity (Fig. 4C and E), we next investigated if exogenous
Wnt5a can potentiate Ab/H2O2-induced cell injury. To this end,
we tested the effect of recombinant Wnt5a on Ab/H2O2
neurotoxicity. As shown in Fig. 4B, compared with Ab/H2O2-
treated cultures, addition of purified recombinant Wnt5a protein
(50–800 ng/ml) increased cell death in a concentration-dependent
manner. This potentiation activity of Wnt5a was completely
abolished when the protein was heat-inactivated (Fig. 4B). This
observation indicates that the biochemical activity of Wnt5a rather
than the mere presence of Wnt5a peptide is essential for the
potentiation. In addition, Foxy5, a Wnt5a-derived hexapeptide
(the same peptide as Box5 but differently modified) that can mimic
Wnt5a-induced activities in malignant melanoma and in breast
cancer cells [55], was also able to potentiate the neurotoxicity of
Ab/H2O2 (Fig. 4D). These results indicate that Wnt5a is sufficient
to elicit neurotoxicity.
Wnt5a (200 ng/ml)+Ab/H2O2). F. Protein levels of pT286-aCaMKII in cortical cultures treated with Ab (500 nM), H2O2 (100 mM), or the combination of
Ab and H2O2. G. Protein levels of pT286-aCaMKII in cortical cultures treated with anti-Wnt5a (4 mg/ml), anti-Fz5 (4 mg/ml) antibodies or Box5
(200 mM), in the presence of Ab (500 nM) and H2O2 (100 mM). * p,0.05; NS, not significant.
doi:10.1371/journal.pone.0022920.g004
Figure 5. Anti-inflammatory factors alleviate Ab neurotoxicity. A. Effects of IL-10 on cell viability of cortical cultures challenged with Ab/H2O2
for 24 hrs. B. Effects of APC. Data (means 6 SEM) are from three independent experiments. * p,0.05; ** p,0.01; # p,0.05 (vs. the group treated
with active IL-10 (1 ng/ml) or APC (1 mg/ml) in the presence of Ab/H2O2).
doi:10.1371/journal.pone.0022920.g005
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The results described above indicate that up-regulated
Wnt5a may mediate Ab neurotoxicity. We then sought to
understand the mechanism by which Wnt5a contributes to Ab
neurotoxicity. Because recent studies revealed a critical role of
Wnt5a in the regulation of inflammatory responses in
peripheral systems, we were interested in determining if Wnt5a
contributes to Ab neurotoxicity by regulating inflammation. To
this end, we first investigated the contribution of neuroin-
flammation to the Ab-induced sensitization of cortical cultures
to H2O2 stress. We found that IL-10, a prototypic anti-
inflammatory cytokine, caused concentration-dependent rescue
effects on Ab toxicity (Fig. 5). IL-10 started to rescue Ab/H2O2-
induced cell death at 0.25 ng/ml and reached a plateau effect at
1 ng/ml (Fig. 5A). Heat-inactivated IL-10 did not have any
rescuing effect (Fig. 5A). To further confirm the involvement of
inflammation in the Ab toxicity, we determined the effect of
activated protein C (APC), another well established anti-
inflammatory protein. The results showed that APC displayed
a similar rescue effect as IL-10 (Fig. 5B). These results indicate
that neuroinflammatory response likely contributes to Ab
neurotoxicity.
Wnt5a regulates proteins that involve in inflammatory
response in cortical cultures
Recent studies reveal an important role of Wnt5a in control of
inflammatory response in non-neuronal peripheral tissues
[56,57,58], but its involvement in regulation of inflammatory
response in nervous systems has not been reported. To investigate
the potential contribution Wnt5a signaling to neuroinflammation,
we examined the effect of Wnt5a on the protein expression of NF-
kB-inducing kinase (NIK), a key positive regulator of inflammation
that controls NF-kB activity by promoting the processing of p100,
the inactive NF-kB2 precursor, to produce the functional p52
subunit [59]. We observed that NIK protein began to increase
5 min after Wnt5a administration (200 ng/ml), and this increase
continued gradually, peaked at 60 min. and stayed at a higher
level afterward (Fig. 6A). Heat-inactivated Wnt5a did not induce a
NIK increase (Fig. 6B), indicating that Wnt5a protein activates
inflammatory pathways in cortical cultures. We also investigated
the effect of Wnt5a on the expression of IkB-a protein, an
inhibitory regulator of inflammation response by sequestering NF-
kB in the cytosol [60]. Interestingly, Wnt5a also induced a gradual
increase of IkB-a (Fig. 6C). In contrast to the NIK increase, the
IkB-a up-regulation did not begin until 30–60 min after Wnt5a
Figure 6. Wnt5a activates molecular pathways critical for inflammatory response. A. The time course of NIK protein dynamics after Wnt5a
(200 ng/ml) treatment. B. Heat-inactivated Wnt5a cannot induce NIK. C. The time course of IkB-a protein dynamics after Wnt5a (200 ng/ml)
treatment. D. Heat-inactivated Wnt5a cannot induce of IkB-a protein. * p,0.05; *** p,0.001 (vs. 0 h in A and C, or vs. vehicle in B and D).
doi:10.1371/journal.pone.0022920.g006
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were recorded (Fig. 6C). It is possible that the lag in up-regulation
of IkB-a functions to resolve the Wnt5a-initiated inflammatory
response.
Inflammatory response culminates with the secretion of an array
of inflammatory cytokines. If Wnt5a indeed induces the inflam-
matory response, specific inflammatory cytokines must be secreted
after Wnt5a administration. Thus, we used ELISA to measure IL-
1b and TNF-a in culture media after Wnt5a treatment for 0.5, 1,
2, 6, 12, or 24 hrs. We observed that Wnt5a stimulation caused a
2.7-fold increase in IL-1b at 12 h, while no change was detected at
other time points (Fig. 7A). On the other hand, TNF-a increased
significantly at 6 h (2.3 fold), 12 h (4.3 fold) and 24 h (3.1 fold)
(Fig. 7C). However, this effect of Wnt5a was completely abolished
when the protein was heat-inactivated (Fig. 7B and D). These
results together strongly suggest that Wnt5a can elicit the
inflammatory response in neuron cultures.
Blockage of Wnt5a signaling impairs Ab-induced
up-regulation of proinflammatory cytokines
Because Ab evoked inflammation-mediated neurotoxicity, we
next investigated the effect of Wnt5a signaling inhibition on the
Ab-elicited inflammatory response. As shown in Fig. 8A, Ab
oligomers (500 nM) significantly increased IL-1b release (3.4
fold; p,0.05). Box5 peptide (200 mM), anti-Wnt5a (2 mg/ml) or
anti-Fz5 (2 ug/ml) antibody suppressed the increase of IL-1b
induced by Ab, by 58%, 59% and 55%, respectively (all 3 with
p,0.05). In contrast, Foxy5 (200 mM), an agonist of Wnt5a,
increased IL-1b release (1.5 fold, compared with Ab alone;
p,0.05; Fig. 8A). Box5, anti-Wnt5a and anti-Fz5 antibodies
caused similar effects on Ab-induced TNF-a release (Fig. 8B).
These results together demonstrate that the suppression of
Wnt5a signaling inhibits Ab-evoked inflammatory responses in
cortical neuron cultures.
Discussion
In this study, we found that non-canonical Wnt5a signaling is
up-regulated in mouse brains prior to AD phenotypes and by Ab
peptide in cortical neuron cultures. The up-regulated Wnt5a
signaling contributes to the inflammation-dependent Ab neuro-
toxicity in cultures. We also found that Wnt5a up-regulates
inflammation regulatory proteins and proinflammatory cytokines
and that Wnt5a is required for the Ab-induced proinflammatory
cytokines. These observations collectively suggest the following
working model (Fig. 8C): accumulation of Ab in the brain
aberrantly up-regulates Wnt5a signaling, which in turn evokes an
inflammatory response that causes neurodegeneration or cell
death in AD brains.
The observed up-regulation of Wnt5a signaling is probably an
early etiologically relevant event during AD development. Both
Wnt5a and Fz5 proteins significantly increase in the APPswe/
PSEN1DE9 hippocampus at the age of 3.5 months (Fig. 2).
Previous studies showed that this AD mouse model started to
accumulate Ab plaques after 4 months of age [61] and did not
develop cognitive impairments until 5–7 months of age [44]. Thus,
Figure 7. Wnt5a evokes cytokine release. A. The temporal profiles
of IL-1b in media of Wnt5a-treated cortical cultures measured by ELISA.
B. Heat-inactivation abolished the activity of Wnt5a in eliciting IL-1b
release. C. The temporal profiles of TNF-a in media after Wnt5a
treatment. D. Effects of heat-inactivation on the Wnt5a activity in
eliciting TNF-a release. * p,0.05 (vs. 0 h in A and C, or vs. vehicle in B
and D).
doi:10.1371/journal.pone.0022920.g007
Figure 8. Wnt5a is critical for Ab-elicited cytokine release. A.
Inhibition of Wnt5a/Fz5 signaling impaired Ab-evoked IL-1b increase in
media. B. Inhibition of Wnt5a/Fz5 signaling impaired Ab-evoked TNF-a
increase in media. ELISA assay of IL-1b (A) and TNF-a (B) secreted in
cortical cultures treated for 12 hrs with Ab (500 nM) or Ab and Box5
(200 mM), anti-Wnt5a (2 mg/ml) or anti-Fz5 (2 mg/ml) antibody. Foxy5, a
Wnt5a agonist, potentiates the cytokine release. * p,0.05; ** p,0.01
(vs. vehicle). C. A working model for the role of Wnt5a signaling in AD
pathogenesis.
doi:10.1371/journal.pone.0022920.g008
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likely prior to the development of major AD phenotypes. This
notion is consistent with the finding that a relatively low
concentration of Ab is able to up-regulate Wnt5a and Fz5
(Fig. 3), suggesting that Wnt5a signaling is a potential target for
slowing or blocking early AD pathogenesis.
Converging lines of evidence support a critical role of the down-
regulation of the canonical Wnt/b-catenin pathway in AD
pathogenesis. In contrast, the involvement of non-canonical Wnt
signaling is less clear. Our findings reveal an early up-regulation of
Wnt5a signaling in the hippocampus of 26Tg AD mice.
Etiological significance of this dysregulation is suggested by the
observation that Wnt5a signaling is necessary for Ab to fully
induce neurotoxicity in cortical cultures. Previous studies demon-
strated that down-regulation of canonical signaling contributed to
Ab neurotoxicity [27,30,34,62]. It is possible that Ab causes
parallel up-regulation of the non-canonical Wnt signaling and
down-regulation of the canonical signaling to initiate neurotoxicity
cascades. The Wnt canonical and non-canonical pathways often
antagonize one another [63]. Thus, another possible scenario is
that Ab may directly down-regulate the canonical pathway, as
suggested by a recent study [33], which consequently causes the
up-regulation of the non-canonical pathway.
Our results reveal a neurotoxic activity of Wnt5a signaling, and
this Wnt5a activity contributes to Ab toxicity in neuron cultures.
Cerpa et al. recently reported that acute administration of
exogenous Wnt5a (500 nM) prevented Ab-induced synaptotoxi-
city within 40 min after Ab oligomer application [36]. Their
results indicate a synapto-protective activity of Wnt5a signaling
soon after Ab exposure. Because Ab-up-regulated Wnt5a does not
occur by 1 hour after Ab treatment in cultures (Fig. 3H) and
500 nM Ab itself does not induce obvious cell death in this period
(Fig. 4A and S1), we reason that basal Wnt5a has a synapto-
protective activity. On the other hand, sustained up-regulation of
Wnt5a, which occurs at 2 hours after Ab treatment (Fig. 3H),
probably potentiates neurotoxicity.
We further found that activation of Wnt5a signaling stimulates
the expression of proinflmmatory cytokine in cortical cultures
(Figs. 6 and 7). This finding indicates that up-regulation of Wnt5a
may mediate Ab-induced neuroinflammation in AD brains
(Fig. 8C). Because the Ab-elicited inflammatory response
(Fig. 8A, 8B) and alleviated Ab-induced neurotoxicity (Fig. 4)
was impaired by the anti-Wnt5a antibody and Box5, Ab likely
induces Wnt5a secretion, although the kinetics of the secretion is
currently unknown. In peripheral non-neuronal systems, Wnt5a is
implicated in inflammation of multiple chronic disorders,
including rheumatoid arthritis [64], sepsis [56], atherosclerosis
[65], melanoma [66], and psoriasis [67]. Our results provide the
initial evidence for a critical role of Wnt5a signaling in the
regulation of inflammatory responses in CNS disorders. Because
the primary cortical cultures used in this study contain neurons
and glia (including microglia and astrocytes), we currently do not
know the specific type of glial cells through which Wnt5a evokes
the observed inflammatory responses. In a recent study, Halleskog
et al. reported that Wnt3a stimulated the expression of
proinflammatory cytokines in microglia [68]. It would be
interesting to know if Wnt5a regulates neuroinflammation by
stimulating the same or different types of glia. Nonetheless, the
findings on Wnt5a and Wnt3a indicate that proteins in the Wnt
family may orchestrate neuroinflammatory response during AD
pathogenesis.
Supporting Information
Figure S1 Cell survival rates revealed by trypan blue
staining. Cortical cultures at 24 hrs after indicated treatments
were used. Dying cells were stained due to the increase of
membrane permeability to the dye.
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